IMPACT-ICO: Trials of Immuno-Modulatory Particles and Colchicine To Improve COVID-19 Outcomes
- Funded by National Health and Medical Research Council (NHMRC)
- Total publications:0 publications
Grant number: GA85492
Grant search
Key facts
Disease
COVID-19Start & end year
20202021Known Financial Commitments (USD)
$676,486.35Funder
National Health and Medical Research Council (NHMRC)Research Location
AustraliaLead Research Institution
University of SydneyResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementationResearch Subcategory
Clinical trial (unspecified trial phase)Special Interest Tags
N/AStudy Type
ClinicalClinical Trial Details
UnspecifiedBroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified
Abstract
The current coronavirus pandemic is highly contagious and carries a significant risk of death. We propose to test a commonly used inflammatory tablet Colchicine and a novel, biodegradable particle which reduces inflamed cells in the hope that this can improve outcomes. The trial will include 240 people needing oxygen treatment and hospital care for the infection. An expert committee together with consumer representatives will oversee the research.